Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating in a report issued on Monday.

A number of other brokerages also recently issued reports on ARWR. Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, September 13th. ValuEngine downgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. Cantor Fitzgerald reiterated a “hold” rating and set a $2.00 price objective (up from $1.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday. Piper Jaffray Companies reiterated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, July 28th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $2.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $2.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at 3.30 on Monday. The firm’s market capitalization is $246.75 million. Arrowhead Pharmaceuticals has a 52-week low of $1.20 and a 52-week high of $8.09. The firm has a 50-day moving average of $2.41 and a 200-day moving average of $1.88.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.06. The firm had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. On average, equities research analysts forecast that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/18/arrowhead-pharmaceuticals-inc-arwr-upgraded-to-outperform-by-william-blair.html.

A number of large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in Arrowhead Pharmaceuticals by 3.4% during the 1st quarter. Geode Capital Management LLC now owns 663,062 shares of the biotechnology company’s stock worth $1,226,000 after buying an additional 21,654 shares during the period. Bank of New York Mellon Corp boosted its position in Arrowhead Pharmaceuticals by 3.7% during the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock worth $581,000 after buying an additional 11,099 shares during the period. LMR Partners LLP acquired a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $467,000. Wells Fargo & Company MN boosted its position in Arrowhead Pharmaceuticals by 144.8% during the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock worth $278,000 after buying an additional 88,933 shares during the period. Finally, Teachers Advisors LLC boosted its position in Arrowhead Pharmaceuticals by 18.0% during the 4th quarter. Teachers Advisors LLC now owns 112,642 shares of the biotechnology company’s stock worth $175,000 after buying an additional 17,201 shares during the period. Institutional investors and hedge funds own 20.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.